James Stewart Blachly MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Tenured Associate Professor of Medicine. Leader of OSU Hereditary Hematologic Neoplasm Program and HALT Clinic Co-Director. Director of Sequencing at OSU Experimental Hematology Lab. Co-Chair of Alliance A-STOR.

Join to view full profile

460 W 10th Ave1st FloorColumbus, OH 43210
Fax+1 614-293-6050

Dr. Blachly is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Blachly's full profile Already have an account?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 2007 - 2011
University of Arkansas For Medical Sciences College of MedicineClass of 2007

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2011 - 2027
AR State Medical License 2010 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Start of enrollment: 2019 Apr 10
TERMINATED
PHASE1, PHASE2

Publications & Presentations

PubMed

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Darren Lee, Yazan Abu-Shihab, Kate Plas, Deedra Nicolet, Krzysztof Mrózek
Leukemia. 2026-08-01
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.
Clive S Zent, Enrico Tiacci, Robert J Kreitman, Tamar Tadmor, Martin S Tallman
Blood. 2026-07-02
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
Naval Daver, James S Blachly, Armin Ghobadi, Anjali Advani, Lori Muffly
Clinical Cancer Research. 2026-07-01

Journal Articles

NF1 Mutations Are Recurrent in Adult Acute Myeloid Leukemia and Confer Poor Outcome
Eunice S Wang, Bayard L Powell, Richard M Stone, John C Byrd, Clara D Bloomfield, Alice Mims, Andrew J Carroll, Jonathan E Kolitz, James S Blachly, Nature

Abstracts/Posters

The Protein Kinase C Inhibitor MS-553 for the Treatment of Chronic Lymphocytic Leukemia
James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Rapid Molecular Diagnostics for Acute Myeloid Leukemia Using Single-Molecule Sequencing
James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Follo...
James S. Blachly, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Precision Medicine Heirarchical Classification Developed Using Variant Allele Frequency (VAF) for Treatment of Older Patients (Pts) with Acute Myeloid Leukemia (AML)...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical and Molecular Characteristics of Acute Myeloid Leukemia (AML) Patients with TP53 Mutations and TP73 Mutations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Editorial Roundup: PennsylvaniaAugust 21st, 2021
NCCN Annual Conference Sheds Light on Treatment Disparities, Significance of the Doctor-Patient Relationship, Supportive Care Issues, and the Latest Guidelines UpdatesMarch 29th, 2017